REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of ...

Revelation Biosciences (REVB) announced Gemini priming attenuates the inflammatory response in human peripheral blood mononuclear cells exposed ...

Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...

Discover how peptides are transforming medical treatments, metabolic conditions and more with fewer side effects than ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Findings reveal macrophages' role in immune modulation through bacterial metabolites, paving the way for improved therapies for infections and inflammation.

Metastatic melanoma is the most aggressive form of skin cancer. In an effort to achieve targeted therapy for metastatic melanoma, researchers recently developed a new radioactive drug that emits alpha ...

These cells have on their surface a range of receptors for inflammatory cytokines, including interferon gamma, TNF, IL-17, IL-6 and IL-1 and others. And when the cells are placed in regions of ...

The firm has a market cap of £65.55 million, a PE ratio of 6.34 and a beta of 1.39. The business’s 50-day simple moving average is GBX 91.03 and its 200 day simple moving average is GBX 116.22.